Rocket Pharmaceuticals, Inc. Amortization of Debt Discount (Premium)
Rocket Pharmaceuticals, Inc. (RCKT) reported Amortization of Debt Discount (Premium) of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2024-02-27
- Rocket Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2023 was $0.00.
- Rocket Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Rocket Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2021 was $753.00K, a 72.70% decline from fiscal 2020.
- Rocket Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2020 was $2.76M, a 23.43% decline from fiscal 2019.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $0.00 10-Q · filed 2022-11-04 | $1.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $1.00K derived: sum of 3 quarters · filed 2024-02-27 | $48.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 | $1.00K derived: sum of 2 quarters · filed 2024-02-27 | $48.00K derived: sum of 3 quarters · filed 2024-02-27 | $164.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $48.00K derived: sum of 2 quarters · filed 2024-02-27 | $164.00K derived: sum of 3 quarters · filed 2024-02-27 | $753.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $163.00K derived: sum of 2 quarters · filed 2022-11-04 | $752.00K 10-Q · filed 2022-11-04 | $1.43M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $116.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $705.00K 10-Q · filed 2022-08-09 | $1.38M derived: sum of 3 quarters · filed 2023-02-28 | $2.05M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $589.00K 10-Q · filed 2022-05-06 | $1.26M derived: sum of 2 quarters · filed 2023-02-28 | $1.93M derived: sum of 3 quarters · filed 2023-02-28 | $2.50M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $673.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.34M derived: sum of 2 quarters · filed 2023-02-28 | $1.91M derived: sum of 3 quarters · filed 2023-02-28 | $2.76M 10-K · filed 2023-02-28 |
| 2020-09-30 | $669.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $1.24M derived: sum of 2 quarters · filed 2021-11-05 | $2.08M 10-Q · filed 2021-11-05 | $3.04M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $572.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $1.42M 10-Q · filed 2021-08-09 | $2.37M derived: sum of 3 quarters · filed 2022-02-28 | $3.29M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $844.00K 10-Q · filed 2021-05-10 | $1.80M derived: sum of 2 quarters · filed 2022-02-28 | $2.71M derived: sum of 3 quarters · filed 2022-02-28 | $3.60M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $952.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.87M derived: sum of 2 quarters · filed 2022-02-28 | $2.75M derived: sum of 3 quarters · filed 2022-02-28 | $3.60M 10-K · filed 2022-02-28 |
| 2019-09-30 | $917.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $1.80M derived: sum of 2 quarters · filed 2020-11-06 | $2.65M 10-Q · filed 2020-11-06 | $3.47M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $883.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.73M 10-Q · filed 2020-08-05 | $2.55M derived: sum of 3 quarters · filed 2021-03-01 | $3.34M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $850.00K 10-Q · filed 2020-05-08 | $1.67M derived: sum of 2 quarters · filed 2021-03-01 | $2.46M derived: sum of 3 quarters · filed 2021-03-01 | $3.21M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $818.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.60M derived: sum of 2 quarters · filed 2021-03-01 | $2.36M derived: sum of 3 quarters · filed 2021-03-01 | $3.06M 10-K · filed 2021-03-01 |
| 2018-09-30 | $787.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $1.54M derived: sum of 2 quarters · filed 2019-11-08 | $2.24M 10-Q · filed 2019-11-08 | $2.24M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $758.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.45M 10-Q · filed 2019-08-08 | $1.45M derived: sum of 3 quarters · filed 2019-08-08 | $1.45M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $696.00K 10-Q · filed 2019-05-09 | $696.00K derived: sum of 2 quarters · filed 2019-05-09 | $696.00K derived: sum of 3 quarters · filed 2019-05-09 | $696.00K derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $0.00 derived: sum of 2 quarters · filed 2019-03-08 | $0.00 derived: sum of 3 quarters · filed 2019-03-08 | $0.00 10-K · filed 2019-03-08 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |